Clinical characteristics and analysis of treatment result in children with Ph‐positive acute lymphoblastic leukaemia in Poland between 2005 and 2017. (31st August 2018)

• Record Type: Journal Article
• Authors: Zawitkowska, Joanna; Lejman, Monika; Zaucha‐Prażmo, Agnieszka; Drabko, Katarzyna; Płonowski, Marcin; Bulsa, Joanna; Romiszewski, Michał; Mizia‐Malarz, Agnieszka; Kołtan, Andrzej; Derwich, Katarzyna; Karolczyk, Grażyna; Ociepa, Tomasz; Ćwiklińska, Magdalena; Trelińska, Joanna; Owoc‐Lempach, Joanna; Niedźwiecki, Maciej; Kiermasz, Aleksandra; Kowalczyk, Jerzy
• Is Part Of: European journal of haematology. Volume 101:Number 4(2018)
• Page Start: 542
• Page End: 548
• Publication Date: 2018-08-31
• Subjects: acute lymphoblastic leukaemia -- chemotherapy -- children -- imatinib -- Philadelphia chromosome; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13142
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Objective: The aim of this study was to analyse the clinical characteristics and outcome of children diagnosed with Ph+ ALL. Material and Methods: A total of 2591 newly diagnosed ALL children were treated in Poland between the years 2005 and 2017. Of those, 44 were diagnosed with Ph(+) ALL. The patients were treated according to protocols: ALL IC‐BFM 2002 and 2009 (26 patients), EsPhALL (12 patients), initially ALL IC‐BFM and then EsPhALL (6 patients). Results: The median of follow‐up in the observed group was 3 years. Overall survival (OS) and event‐free survival (EFS) of Ph+ ALL group were 0.73 and 0.64. OS and EFS of patients after HSCT were 0.78 and 0.66, while without HSCT were 0.6 and 0.6, P = 0.27 and 0.63. OS was 0.8 for patients treated with chemotherapy plus imatinib and 0.61 for chemotherapy alone, P = 0.22, while EFS was 0.66 (imatinib therapy) and 0. 61 (without imatinib), P = 0.41. Conclusion: Our study suggests that adding imatinib to intensive chemotherapy seems to improve outcome. However, this study was limited by a small number of patients and a variety of chemotherapy regimens with or without imatinib.